Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | FPR2 | P25090 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | AKT1 | P31749 | 1/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.39 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | PDE2A | O00408 | 1/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3277620 | 0.90 | CYP3A4 (0.47) | FPR2TAAR1ROCK1HSD17B10GSK3B | |
| SCHEMBL3279268 | 0.86 | GSK3B (0.45) | KMT2AMEN1ROCK1GSK3BCYP3A4 | |
| SCHEMBL3273874 | 0.80 | PTGES (0.39) | ROCK1GSK3BCYP3A4MAPK1PDE2A | |
| SCHEMBL3280869 | 0.80 | LMNA (0.43) | KMT2AMEN1ROCK1GSK3BCYP3A4 | |
| SCHEMBL3273959 | 0.79 | ROCK1 (0.44) | KMT2AAKT1ROCK1GSK3BCYP3A4 | |
| SCHEMBL3275166 | 0.78 | GSK3B (0.42) | KMT2AMEN1ROCK1GSK3BCYP3A4 | |
| SCHEMBL3273858 | 0.78 | GSK3B (0.45) | KMT2AROCK1GSK3BCYP3A4MAPK1 | |
| SCHEMBL3273302 | 0.78 | CYP3A4 (0.46) | KMT2AAKT1ROCK1GSK3BCYP3A4 | |
| SCHEMBL3145226 | 0.75 | ROCK1 (0.42) | KMT2AROCK1GSK3BCYP3A4MAPK1 | |
| SCHEMBL3273280 | 0.75 | TSHR (0.56) | KMT2AMEN1ROCK1GSK3BCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8592436-B2 | Arylamide pyrimidone derivatives | SANOFI (FR) | 2013-11-26 | — | — | US | claimed |
| EP-2148866-B1 | ARYLAMIDE PYRIMIDONE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SANOFI SA (FR) | 2013-07-17 | — | — | EP | claimed |
| US-20100087460-A1 | ARYLAMIDE PYRIMIDONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2010-04-08 | — | — | US | claimed |
| EP-1992620-A1 | Arylamide pyrimidone derivatives for the treatment of neurodegenerative diseases | Sanofi-Aventis (FR) | 2008-11-19 | — | — | EP | claimed |
| US-8592436-B2 | Arylamide pyrimidone derivatives | SANOFI (FR) | 2013-11-26 | — | — | US | disclosed |
| EP-2148866-B1 | ARYLAMIDE PYRIMIDONE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SANOFI SA (FR) | 2013-07-17 | — | — | EP | disclosed |
| US-20100087460-A1 | ARYLAMIDE PYRIMIDONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2010-04-08 | — | — | US | disclosed |
| EP-2148866-A2 | ARYLAMIDE PYRIMIDONE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | Sanofi-Aventis (FR) | 2010-02-03 | — | — | EP | disclosed |
| WO-2008155669-A2 | ARYLAMIDE PYRIMIDONE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SANOFI-AVENTIS (FR) | 2008-12-24 | — | — | WO | disclosed |
| EP-1992620-A1 | Arylamide pyrimidone derivatives for the treatment of neurodegenerative diseases | Sanofi-Aventis (FR) | 2008-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087460-A1 | ARYLAMIDE PYRIMIDONE DERIVATIVES | DHFR, XDH, HPRT1 | KMT2A 2609/4885FPR2 823/4885MEN1 1547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.